Medium impact
Chimeric Antigen Receptor (CAR) T-cell Therapy - Medicare Advantage (Revised)
Humana·Effective Sep 2, 2025
CPT 38227, in plain terms, covers A medical facility receives and prepares CAR-T cells (specially engineered immune cells) for treatment administration to a patient. CPT 38227 is referenced in 1 tracked payer policy change from Humana. For billers and coders, staying current on payer-specific coverage criteria, reimbursement rules, and prior-authorization requirements for CPT 38227 is critical to clean claim submission. Each entry below links to the full policy analysis with effective dates and action steps.
Official descriptor: CPT 38227 on AAPC
Related
Get alerts for changes like this
Save a search and receive a daily digest whenever a new policy change matches your filters.